Gilead Sciences Inc. Purchases New Stake in Kronos Bio, Inc. (NASDAQ:KRON)

Gilead Sciences Inc. acquired a new position in shares of Kronos Bio, Inc. (NASDAQ:KRON) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 188,567 shares of the company’s stock, valued at approximately $179,000. Kronos Bio makes up approximately 0.0% of Gilead Sciences Inc.’s holdings, making the stock its 16th largest position. Gilead Sciences Inc. owned approximately 0.31% of Kronos Bio at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Kennedy Capital Management LLC boosted its position in shares of Kronos Bio by 8.7% during the 4th quarter. Kennedy Capital Management LLC now owns 149,251 shares of the company’s stock worth $142,000 after acquiring an additional 12,007 shares in the last quarter. Deltec Asset Management LLC acquired a new position in Kronos Bio during the fourth quarter worth about $190,000. Peapod Lane Capital LLC bought a new position in shares of Kronos Bio in the fourth quarter worth about $534,000. Finally, Renaissance Technologies LLC boosted its stake in shares of Kronos Bio by 19.7% in the 4th quarter. Renaissance Technologies LLC now owns 1,171,808 shares of the company’s stock valued at $1,113,000 after purchasing an additional 192,754 shares in the last quarter. 64.09% of the stock is owned by institutional investors.

Kronos Bio Price Performance

KRON stock opened at $0.89 on Friday. Kronos Bio, Inc. has a 1 year low of $0.69 and a 1 year high of $1.60. The stock has a market cap of $54.14 million, a price-to-earnings ratio of -0.62 and a beta of 1.78. The company has a 50 day simple moving average of $0.90 and a 200 day simple moving average of $0.94.

Kronos Bio (NASDAQ:KRON) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.13). The firm had revenue of $2.27 million for the quarter, compared to analyst estimates of $1.00 million. Kronos Bio had a negative net margin of 867.66% and a negative return on equity of 64.55%. On average, equities research analysts anticipate that Kronos Bio, Inc. will post -1.36 EPS for the current fiscal year.

About Kronos Bio

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.